Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HH160 in Advanced or Metastatic Solid Tumors
NCT07623369Phase 1Recruiting
- Sponsor
- Huahui Health
- Start
- Jun 2026
- Primary completion
- Aug 2027
- Countries
- 2
01
Overview
Phase 1, open-label trial of HH160 in solid tumor, non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC) and 9 more (3 arms), sponsored by Huahui Health. Primary endpoints: Treatment-Emergent Adverse Events and Serious Adverse Events at 2 years, Maximum Tolerated Dose at 1 month and 2 more. Started Jun 2026; status: recruiting.
02
Drugs
HH160
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)hepatocellular carcinoma (HCC)colorectal cancer (CRC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07623369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07623369.